Anzeige
❌
Mehr »
Dienstag, 17.11.2026 - Börsentäglich über 12.000 News
GBC-Kursziel 2,00 CAD bis Juni 2027, Kurs 0,67 CAD: Verdreifachung drin?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0EAT9 | ISIN: BE0003818359 | Ticker: GXE
Xetra
16.11.26 | 13:17
31,060 Euro
-2,77 % -0,860
Branche
Biotechnologie
Aktienmarkt
BEL Mid
AMX
1-Jahres-Chart
LAKEFRONT BIOTHERAPEUTICS NV Chart 1 Jahr
5-Tage-Chart
LAKEFRONT BIOTHERAPEUTICS NV 5-Tage-Chart
RealtimeGeldBriefZeit
31,10031,50016.11.
31,06031,32016.11.

Aktuelle News zur LAKEFRONT BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoLakefront BioTherapeutics initiates new €50M share repurchase program1
LAKEFRONT BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
MoLakefront Biotherapeutics: Lakefront Initiates New €50 Million Share Repurchase Program Following Completion of Initial Share Repurchase Program278Mechelen, Belgium; November 16, 2026; 7.30 AM CET regulated information - Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced the initiation of a new share repurchase program of up...
► Artikel lesen
DoLakefront Biotherapeutics NV - 6-K, Report of foreign issuer4
MiLakefront BioTherapeutics GAAP EPS of €0.20, revenue of €26.1M9
MiLakefront Biotherapeutics Reports Nine Months 2026 Financial Results and Provides Business Update601Gamgertamig poster accepted for presentation at the 2026 ASH1 Annual Meeting, featuring data from ongoing Phase 1b studies that suggest potential to retain remission after B cell reconstitution, maintained...
► Artikel lesen
04.11.Lakefront Biotherapeutics Announces Poster Presentation at the 2026 American Society of Hematology Meeting8
02.11.Lakefront Biotherapeutics Welcomes Dr. Mehdi Shahidi to its Board of Directors2
02.11.Lakefront Biotherapeutics NV - 6-K, Report of foreign issuer1
20.10.Lakefront Biotherapeutics NV - 6-K, Report of foreign issuer6
20.10.Morgan Stanley initiates Lakefront Biotherapeutics stock with Equalweight rating10
15.10.Lakefront Biotherapeutics finally finds buyer for unwanted cell therapy pipeline16
14.10.Lakefront Biotherapeutics: Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics8
08.10.Lakefront Biotherapeutics: Lakefront Receives Transparency Notification from Bank of America595Mechelen, Belgium; October 8, 2026, 22.01 CET; regulated information - Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America. Pursuant...
► Artikel lesen
06.10.Lakefront Biotherapeutics NV - 6-K, Report of foreign issuer1
23.09.Lakefront Biotherapeutics Stock Rises 4% After Share Repurchase Update5
23.09.TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday1
23.09.RBC stuft Lakefront Biotherapeutics hoch - Potenzial bei Autoimmun-Medikament treibt Kursziel13
23.09.RBC upgrades Lakefront Biotherapeutics stock rating on autoimmune drug potential7
23.09.Lakefront Biotherapeutics NV - 6-K, Report of foreign issuer-
08.09.Lakefront Biotherapeutics NV - 6-K, Report of foreign issuer3
1 2 3 4 Weiter >>
71 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1